治疗后抗血小板治疗降低动脉瘤性蛛网膜下腔出血所致迟发性脑缺血风险
该回顾性病例对照研究基于2003年1月至2016年6月机构观察队列的994例蛛网膜下腔出血患者,最终分析580例,其中329例接受治疗后抗血小板药物。阿司匹林使用与迟发性脑缺血风险降低独立相关(P<.001,调整OR=0.41,95%CI 0.24-0.65),并与6个月良好结局相关(P=.02,调整OR=1.78,95%CI 1.06-2.98),仅与轻微出血事件相关(P=.02),与主要出血事件无显著相关(P=.51)。
要点
- 阿司匹林使用与迟发性脑缺血风险降低独立相关(调整OR=0.41,95%CI 0.24-0.65)。
- 阿司匹林使用与6个月良好结局相关(调整OR=1.78,95%CI 1.06-2.98)。
- 在本队列中,双联抗血小板治疗对迟发性脑缺血风险无额外获益,但增加主要出血事件可能性。
核心结论
- 规律给予阿司匹林可能对蛛网膜下腔出血患者的迟发性脑缺血风险和结局产生积极影响,且不增加临床相关出血事件风险。
- 在本蛛网膜下腔出血队列中,双联抗血小板治疗对迟发性脑缺血风险无额外获益,但增加主要出血事件的可能性。
研究设计与样本
- 回顾性病例对照研究,基于2003年1月至2016年6月机构观察队列的994例蛛网膜下腔出血患者。
- 最终分析580例,其中329例接受治疗后抗血小板药物(阿司匹林联合或不联合氯吡格雷),与未接受抗血小板治疗的对照组比较。
主要发现
- 阿司匹林使用与迟发性脑缺血风险降低独立相关(P<.001,调整OR=0.41,95%CI 0.24-0.65)。
- 阿司匹林使用与6个月良好结局相关(P=.02,调整OR=1.78,95%CI 1.06-2.98)。
- 阿司匹林仅与轻微出血事件相关(P=.02),与主要出血事件无显著相关(P=.51)。
- 在本队列中,双联抗血小板治疗对迟发性脑缺血风险无额外获益,但增加主要出血事件的可能性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Delayed cerebral ischemia (DCI) has a strong impact on outcome of patients with aneurysmal subarachnoid hemorrhage (SAH). Positive effect of antiplatelet therapy on DCI rates has been supposed upon smaller SAH series. OBJECTIVE: To analyze the benefit/risk profile of antiplatelet use in SAH patients. METHODS: This retrospective case-control study was based on institutional observational cohort with 994 SAH patients treated between January 2003 and June 2016. The individuals with postcoiling antiplatelet therapy (aspirin with/without clopidogrel) were compared to a control group without antiplatelet therapy. Occurrence of DCI, major/minor bleeding events in the follow-up computed tomography scans, and favorable outcome at 6 mo after SAH (modified Rankin scale < 3) were compared in both groups. RESULTS: Of 580 patients in the final analysis, 329 patients received post-treatment antiplatelet medication. There were no significant differences between the compared groups with regard to basic outcome confounders. Aspirin use was independently associated with reduced DCI risk (P < .001, adjusted odds ratio = 0.41, 95% confidence interval 0.24-0.65) and favorable outcome (P = .02, adjusted odds ratio = 1.78, 95% confidence interval 1.06-2.98). Regarding bleeding complications, aspirin was associated only with minor bleeding events (P = .02 vs P = .51 for major bleeding events). CONCLUSION: Regular administration of aspirin might have a positive impact on DCI risk and outcome of SAH patients, without increasing the risk for clinically relevant bleeding events. In our SAH cohort, dual antiplatelet therapy showed no additional benefit on DCI risk, but increased the likelihood of major bleeding events.
引用
- Darkwah Oppong M, Gembruch O, Pierscianek D, et al. Post-treatment Antiplatelet Therapy Reduces Risk for Delayed Cerebral Ischemia due to Aneurysmal Subarachnoid Hemorrhage. Neurosurgery. 2019. PMID: 30544176. doi:10.1093/neuros/nyy550
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。